News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer -Median Survival: 13.5 months (vs. 6.7-9.8) -21 of 29 terminal patients treated since 2022 are alive -No toxicities reported (Nasdaq: BCTX) becoming a ray of hope in the toughest fight. #CancerBreakthrough https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html